Recent Updates
Recently added Catalysts

Regeneron Pharmaceuticals, Inc.

REGNFDA catalysts, PDUFA dates & pipeline intelligence
$955.47
▲ +4.28 · +0.45%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Quarterly Cash
Unlock full REGN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $591.5252W HIGH $991.73
Volume
1.17 M
Value Traded
1.11 B
Short % Float
2.23%
Days to Cover
2.7
+3.86%Week
+19.98%1 Month
+18.55%3 Month
+51.74%6 Month
+24.26%5 Year
+2,924.28%All Time

Cash Data

Unlock REGN cash position
  • Cash FlowProfitable
  • SEC Filing

Key Stats

Market Cap
98.84 B
EPS (TTM)
46.57
P/E Ratio
20.52
Ent. Value
81.97 B
Total Shares
103.45 M
Float Shares
99.55 M
Insiders
3.75%
Institutions
91.60%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA Date
cemdisiran (C5 RNAi therapy)
generalized myasthenia gravis (gMG)
PDUFARNA-Based TherapiesNervous System
Unlock every REGN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

REGN Catalyst Timeline

Dated clinical, regulatory and corporate events for Regeneron Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Regeneron Pharmaceuticals, Inc.

1446Total events
37Upcoming
728Tier-1 (high impact)
2011 to 2031Coverage

Upcoming catalysts 2

T1Interim Analysis
Subscribe to view catalyst details
PozelimabApproved
T1FDA Approval
Subscribe to view catalyst details
PasatruApproved

Event history 50

▲Oral PresentationbaloncibartPresentation
Baloncibart POTS Phase 2 data presented at AAS 37th International Symposium
postural orthostatic tachycardia syndrome (POTS)source ↗
▲Topline ReadoutbaloncibartClinical Data
Baloncibart Phase 2 PINNACLE topline results in POTS presented at AAS
postural orthostatic tachycardia syndrome (POTS)source ↗
●R&D DayPresentation
Regeneron Roundtable virtual investor event on MASH pipeline
cardiometabolic and MASH pipelinesource ↗
▲PublicationCIDEBsiRNAPresentation
CIDEBsiRNA first-in-human results published in The New England Journal of Medicine
MASLDsource ↗
▲Oral PresentationCIDEBsiRNAPresentation
CIDEBsiRNA Phase 1/2 data presented in oral session at AASLD The Liver Meeting 2026
MASLDsource ↗
▲Topline ReadoutCIDEBsiRNAClinical Data
First-in-human Phase 1/2 results of CIDEBsiRNA in MASLD reported
metabolic dysfunction-associated steatotic liver disease (MASLD)source ↗
▲Quarterly UpdateCorporate
Regeneron reported Q3 2026 financial and operating results
source ↗
▲PreprintmaftivimabPresentation
Preprint of maftivimab in vitro and non-human primate data against Bundibugyo virus available
Bundibugyo virus diseasesource ↗
▲Trial InitiationmaftivimabTrial
Maftivimab monotherapy added to PARTNERS trial for Bundibugyo virus disease outbreak
Bundibugyo virus diseasesource ↗
▲Partnership / LicenseInmazebApprovedCorporate
Regeneron extends BARDA agreement for additional Inmazeb supply (~$270M)
Ebola disease caused by Orthoebolavirus zairensesource ↗
Unlock the full REGN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How REGN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-23Libtayo (cemiplimab) Phase 2 data presentation Phase 2
Unlock 14 more REGN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
56
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma
(rank 8 of 687)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
EYLEA HD
LIBTAYO
EYLEA
Praluent
Evkeeza
Showing 90 of 231 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Cenvacibart BiologicsNCT07876492Secondary StrokePhase 3 NOT YET_RECRUITING 6,106Dec 15, 2029
REGN7508 Small MoleculesNCT07175428Atrial Fibrillation (AF)Phase 3 RECRUITING 19,192Apr 21, 2027
REGN7508 Small MoleculesNCT07318610Peripheral Artery Disease (PAD)Phase 3 RECRUITING 7,050Nov 16, 2029
REGN7508 Small MoleculesNCT07410117Cancer-Associated Thrombosis (CAT)Phase 3 RECRUITING 1,120May 6, 2030
REGN7508 Small MoleculesNCT07213778Symptomatic Venous Thromboembolism (VTE)Phase 3 RECRUITING 2,000Jul 16, 2027
Fianlimab BiologicsNCT05785767Advanced Non-Small Cell Lung CancerPhase 2/3 ACTIVE NOT_RECRUITING 149Sep 28, 2027
Fianlimab BiologicsNCT06848088MelanomaPhase 3 ACTIVE NOT_RECRUITING 3,698Oct 9, 2030
Fianlimab BiologicsNCT05800015Non-small Cell Lung CancerPhase 2/3 ACTIVE NOT_RECRUITING 160Dec 23, 2031
Fianlimab BiologicsNCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)Phase 2 RECRUITING 120Dec 28, 2030
Fianlimab BiologicsNCT06161441Resectable Non-small Cell Lung CancerPhase 2 ACTIVE NOT_RECRUITING 195Nov 4, 2029
mibavademab BiologicsNCT07220772Monogenic ObesityPhase 3 RECRUITING 4Apr 21, 2028
mibavademab BiologicsNCT07235917Functional Hypothalamic AmenorrheaPhase 2 RECRUITING 34May 17, 2028
ALN-CIDEB Small MoleculesNCT06836609Metabolic Dysfunction-Associated Steatotic Liver DiseasePhase 3 ACTIVE NOT_RECRUITING 1,618Aug 17, 2027
ALN-CIDEB Small MoleculesNCT07631637Metabolic Dysfunction-Associated SteatohepatitisPhase 2 RECRUITING 360Jan 29, 2029
Olatorepatide PeptidesNCT07896265Overweight or Obesity Without DiabetesPhase 3 NOT YET_RECRUITING 3,000Jan 23, 2029
Olatorepatide PeptidesNCT07431086Overweight or ObesityPhase 2 ACTIVE NOT_RECRUITING 480Dec 18, 2026
Olatorepatide PeptidesNCT07830329Hidradenitis SuppurativaPhase 2 RECRUITING 300Dec 22, 2028
ALN-PNP Small MoleculesNCT05648214Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Phase 2 RECRUITING 376Aug 10, 2027
REGV131 Small MoleculesNCT06379789Hemophilia BPhase 1/2 RECRUITING 130Aug 14, 2047
ALN-ANG3 Small MoleculesNCT07271186Diabetic Kidney Disease (DKD)Phase 2 RECRUITING 195Oct 13, 2028
REGN9933 Small MoleculesNCT07759167End-Stage Kidney Disease (ESKD)Phase 1 RECRUITING 36Apr 2, 2027
Pozelimab BiologicsNCT06541704Age-related Macular Degeneration (AMD)Phase 3 RECRUITING 975Apr 9, 2033
Pozelimab BiologicsNCT05070858Generalized Myasthenia GravisPhase 3 ACTIVE NOT_RECRUITING 288Nov 11, 2028
Pozelimab BiologicsNCT07230834Geographic Atrophy (GA)Phase 1 RECRUITING 54Jul 3, 2028
linvoseltamab BiologicsMarketedNCT07222761Relapsed and/or Refractory Multiple Myeloma (RRMM)Approved RECRUITING 915Aug 23, 2034
Unlock the REGN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every REGN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
baloncibart postural orthostatic tachycardia syndrome (POTS)Phase 22026-11-12baloncibart 450 mg day 8: LS mean difference -11.4 bpm, nominal p 0.0007; baloncibart 150 mg day 8: LS mean difference -9.5 bpm, nominal p 0.0045; baloncibart 450 mg day 29: LS mean difference -7.4 bpm, nominal p 0.0124Read MorePOTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic SymptomsRead More
Scroll for more · summaries link to the source press release
Unlock every REGN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock REGN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Pitofsky JasonOfficer (SVP Controller)Option 1,500 5,772 held$726.53 11/04/2026
Unlock the full REGN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in REGN

Fund % of Portfolio Current MV Shares Owned Activity
INTEGRAL HEALTH ASSET MANAGEMENT, LLC 1 % (-67.7 %) 24.94 M 40.00 K -52.94% ( -45.00 K)
Unlock every fund holding REGN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in REGN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see REGN ownership
Insider and institutional ownership, quarter by quarter.

REGN Short Interest

Shares sold short, counted twice a month.

2.23%
Short % of Float
of tradable shares sold short
2.2M
Shares Sold Short
+3.8% vs prior count
2.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
810.9K
Avg Daily Volume
the average used for days to cover
Unlock REGN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-13
Unlock REGN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live REGN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock REGN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How REGN ranks across every disease it competes in

Competitive Position is a premium feature
See how REGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

REGN News

REGN
Nov 12, 2026
REGNPhases
▲ +0.5%today

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

Regeneron announced positive Phase 2 trial results for baloncibart, a monoclonal antibody for POTS. A single dose significantly reduced heart rate upon standing and improved symptoms for four weeks. The trial showed promising biomarker changes consistent with increased blood volume. A Phase 3 trial is planned for 2027.

Read more →
REGN
Nov 8, 2026
REGNPhases

CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

Regeneron Pharmaceuticals announced positive results from a first-in-human trial of CIDEBsiRNA, which showed up to 80% reduction in liver fat in MASLD patients. The effects were sustained for 36 weeks, with 62% of participants normalizing liver fat levels. The findings were presented at AASLD and published in The New England Journal of Medicine.

Read more →
REGN
Nov 2, 2026
REGNConferences/Events

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals will participate in three upcoming investor conferences. The events include the Jefferies Global Healthcare Conference on November 17, the Evercore Healthcare Conference on December 1, and Citi's Global Healthcare Conference on December 2. Webcasts will be available on the company's website.

Read more →
REGN
Oct 30, 2026
REGNGeneral
▲ +13.3%on this newsshared move

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Regeneron reported a strong third quarter for 2026, with revenues rising 36% to $5.1 billion. Key products like Dupixent and EYLEA HD saw significant sales growth. The company also expanded its collaboration with Sanofi, adding next-generation antibodies, and received FDA approval for Pasatru for fibrodysplasia ossificans progressiva.

Read more →
REGN
Oct 26, 2026
REGNFDA Updates

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Regeneron Pharmaceuticals has extended its agreement with BARDA to supply additional doses of Inmazeb, an FDA-approved treatment for Ebola. The updated agreement, valued at approximately $270 million, ensures the availability of Inmazeb through 2031. The treatment has shown a 55% reduction in mortality in clinical trials, reinforcing U.S. preparedness against Ebola outbreaks.

Read more →
REGN
Oct 25, 2026
REGNPhases

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Regeneron announced that longer-term data from the Phase 3 C-POST trial show a significant increase in overall survival for patients with high-risk cutaneous squamous cell carcinoma treated with Libtayo. The risk of death was reduced by 37% at a median follow-up of 44 months. The results were presented at the ESMO Congress 2026, reinforcing Libtayo's role as a standard of care.

Read more →
REGN
Oct 16, 2026
REGNFDA Updates

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

The CHMP has issued a positive opinion recommending an updated dosing regimen for Libtayo (cemiplimab) that allows for administration every six weeks after an initial 12-week period. This change could improve patient convenience by reducing the frequency of treatments and potentially shortening infusion times. The European Commission is expected to make a final decision soon.

Read more →
REGN
Oct 12, 2026
REGNPhases

Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

Regeneron Pharmaceuticals announced positive 84-week results from the Phase 3 OPTIMA trial for Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP). The treatment showed sustained efficacy in preventing new heterotopic ossification lesions and reducing disease flare-ups. The trial demonstrated a well-tolerated safety profile, with no new lesions observed in treated patients during the extension phase. Regeneron plans to initiate a Phase 3 trial for adolescents and children with FOP later this year.

Read more →
REGN
Oct 6, 2026
REGNConferences/Events

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Regeneron Pharmaceuticals presented new clinical research at the ESMO Congress 2026, highlighting advancements in cancer treatment, particularly with Libtayo for cutaneous squamous cell carcinoma (CSCC). The data includes late-breaking Phase 3 results demonstrating improved survival outcomes and a Phase 2 analysis of neoadjuvant treatment. Additionally, new approaches to manage cancer-associated thrombosis were discussed.

Read more →
REGN
Oct 1, 2026
REGNPhases

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Regeneron Pharmaceuticals announced promising results for ubamatamab in patients with advanced low-grade serous ovarian cancer (LGSOC). In a Phase 1/2 trial, the drug demonstrated a 73% objective response rate and an 11-month median progression-free survival. Regeneron plans to advance ubamatamab into a confirmatory Phase 3 trial, aiming to address the unmet needs in this challenging cancer subtype.

Read more →
REGN
Oct 1, 2026
REGNPhases

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

Regeneron Pharmaceuticals announced positive results from the Phase 2 COURAGE trial, which demonstrated that trevogrumab can prevent significant muscle loss during GLP-1 receptor agonist-induced weight loss. The trial showed that trevogrumab preserved nearly 70% of muscle mass compared to semaglutide alone. These findings were presented at the EASD Annual Meeting and indicate potential for future clinical development.

Read more →
REGN
Sep 24, 2026
REGNConferences/Events

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

Regeneron Pharmaceuticals, Inc. announced that it will report its third quarter 2026 financial and operating results on October 30, 2026. The company will also host a conference call and webcast at 8:30 AM ET on the same day. Participants can access the call via the company's website or by telephone after registering in advance.

Read more →
REGN
Aug 19, 2026
REGNFDA Updates

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Regeneron Pharmaceuticals announced FDA approval for Pasatru (garetosmab-grts), the first treatment for fibrodysplasia ossificans progressiva (FOP). The approval is based on the OPTIMA trial, which showed a 90% reduction in new heterotopic ossification lesions and a significant decrease in flare-ups. This treatment represents a crucial advancement for the approximately 900 individuals diagnosed with this ultra-rare condition.

Read more →
REGN
Jul 31, 2026
REGNGeneral

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Regeneron Pharmaceuticals has awarded the 2026 Regeneron Prize for Creative Innovation to early-career scientists from NYU, Stanford, and Rensselaer Polytechnic Institute. The awards, totaling $150,000, recognize innovative proposals aimed at advancing biomedical research. Winners include Simon Vecchioni, Siyuan Du, and Frank Peters, each contributing unique projects with the potential to enhance human health.

Read more →
REGN
Jul 30, 2026
REGNGeneral
▲ +6.2%on this newsshared move

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Regeneron Pharmaceuticals reported strong financial results for Q2 2026, with revenues rising 17% to $4.3 billion. Key products like Dupixent and EYLEA HD achieved record sales. The company also announced the acceptance of regulatory submissions for cemdisiran by the FDA and EMA. Overall, Regeneron continues to invest in its pipeline and manufacturing capabilities.

Read more →
REGN
Jun 25, 2026
REGNConferences/Events

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Regeneron Pharmaceuticals, Inc. will announce its second quarter 2026 financial and operating results on July 30, 2026. The announcement will be followed by a conference call and webcast at 8:30 AM Eastern Time. Participants can access the call via a registration link, and a replay will be available for 30 days.

Read more →
REGN
Jun 22, 2026
REGNFDA Updates

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Regeneron Pharmaceuticals announced that the FDA and EMA have accepted regulatory submissions for cemdisiran, a potential treatment for generalized myasthenia gravis (gMG). The FDA's Priority Review could lead to approval by November 2026, while a European decision is expected in late 2027. Cemdisiran, administered subcutaneously every 12 weeks, shows promise based on data from a significant Phase 3 trial.

Read more →
REGN
Jun 4, 2026
REGNGeneral

regeneron to highlight progress across its metabolic disease ophthalmology and rare disease pipelines at ada and endo

regeneron to highlight progress across its metabolic disease ophthalmology and rare disease pipelines at ada and endo

Read more →
REGN
May 29, 2026
REGNFDA Updates

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Regeneron Pharmaceuticals announced that the World Health Organization has recommended maftivimab, a component of the Inmazeb cocktail, for evaluation in clinical trials targeting the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda. This recommendation follows the WHO's declaration of the outbreak as a public health emergency. Regeneron is coordinating efforts with health authorities to facilitate the trials and has existing supplies of Inmazeb available for immediate use.

Read more →

About Regeneron Pharmaceuticals, Inc.

Tarrytown, NY 15,410 employees regeneron.com
Headquarters777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
BIOPHARMAWATCH ELITE
Trade the next REGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime